TIANXIN PHARMA(603235)

Search documents
天新药业:中信证券股份有限公司关于江西天新药业股份有限公司2023年度持续督导报告书
2024-05-06 09:40
中信证券股份有限公司 关于江西天新药业股份有限公司 2023年度持续督导报告书 | 上市公司:江西天新药业股份有限公司(以下简称"天新药业"、"公司") | | | --- | --- | | 保荐人名称:中信证券股份有限公司(以下简称"中信证券"或"保荐人") | | | 保荐代表人姓名:丁元 | 联系电话:021-20262071 | | 保荐代表人姓名:庄林 | 联系电话:021-20262071 | 经中国证券监督管理委员会《关于核准江西天新药业股份有限公司首次公开 发行股票的批复》(证监许可[2022]1220 号)核准,并经上海证券交易所同 意,公司于 2022 年 7 月 1 日首次向社会公开发行人民币普通股(A 股)4,378.00 万股,每股发行价格为 36.88 元,募集资金总额为 1,614,606,400.00 元,扣除各 类发行费用之后实际募集资金净额 1,517,233,100.00 元。中汇会计师事务所(特 殊普通合伙)于 2022 年 7 月 7 日对江西天新药业股份有限公司首次公开发行股 票的资金到位情况进行了审验,并出具了"中汇会验[2022]5910 号"验资报 告。20 ...
天新药业:中信证券股份有限公司关于江西天新药业股份有限公司2023年度持续督导工作现场检查报告
2024-05-06 09:40
中信证券股份有限公司 关于江西天新药业股份有限公司 2023 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定,中信证券股份有限公司(以下简称"中信证券"或"保荐 人")作为正在对江西天新药业股份有限公司(以下简称"天新药业""公司""上 市公司")进行持续督导工作的保荐人,对 2023 年度(以下简称"本持续督导期 间")的规范运作情况进行了现场检查,现就现场检查的有关情况报告如下: 一、本次现场检查的基本情况 (一)保荐人 中信证券股份有限公司 (二)保荐代表人 丁元、庄林 (三)现场检查人员 庄林、杨嘉歆、徐亮 (四)现场检查时间 2024 年 4 月 9 日、2024 年 4 月 12 日、2024 年 4 月 24 日-2024 年 4 月 25 日 (五)现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查,具体检查内容详见本报告"二、本次现 ...
天新药业:关于以集中竞价交易方式回购公司股份的进展公告
2024-05-05 07:36
证券代码:603235 证券简称:天新药业 公告编号:2024-029 重要内容提示: | 回购方案首次披露日 | 2024/1/23 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 1 | 22 | 日~2025 | 年 | 1 | 21 | 日 | | 预计回购金额 | 60,000,000 元~120,000,000 元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 股 1,368,268 | | | | | | | | 累计已回购股数占总股本比 | 0.3125% | | | | | | | | 例 | | | | | | | | | 累计已回购金额 | 28,417,490.56 元 | | | | | | | | 实际回购价格区间 | 元/股~22.61 元/股 19.17 | | | | ...
天新药业(603235) - 2024 Q1 - 季度财报
2024-04-29 10:28
特此公告 江西天新药业股份有限公司董事会 2024 年 4 月 30 日 公司负责人:许江南 主管会计工作负责人:罗雪林 会计机构负责人:梁亮 母公司利润表 | --- | --- | --- | |--------------|-------------------|-------------------| | 项目 | 2024 年第一季度 | 2023 年第一季度 | | 一、营业收入 | 497,412,857.03 | 578,385,715.56 | | 减:营业成本 | 317,621,405.06 | 405,616,576.96 | | 税金及附加 | 4,905,144.54 | 3,902,759.18 | | 销售费用 | 3,079,008.12 | 5,272,037.85 | | 管理费用 | 25,214,608.45 | 28,643,435.92 | | 研发费用 | 9,686,583.82 | 6,552,836.78 | | 财务费用 | -25,750,850.05 | 156,951.62 | 14 / 17 2024 年第一季度报告 | --- | --- | ...
天新药业:关于2024年第一季度经营数据的公告
2024-04-29 10:25
证券代码:603235 证券简称:天新药业 公告编号:2024-028 江西天新药业股份有限公司 关于 2024 年第一季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定,现将江西天新药业股份有限公司(以下简称"公司") 2024 年第一季度经营数据(未经审计)公告如下: 一、 2024年第一季度主要经营数据 1、主营业务分产品情况 单位:元 币种:人民币 | 产品分类 | 2024 | 年 1-3 月收入 | 2023 | 年 1-3 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | 族维生素 B | | 409,717,324.36 | | 513,544,458.92 | | -20.22% | | 其他维生素 | | 57,064,938.52 | | 37,015,659.79 | | 54.16% | | 精细化工品 | | 22,7 ...
公司事件点评报告:价格逐步回升,利润增长有望逐步恢复
华鑫证券· 2024-04-24 13:30
证 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 告 司 究 报 公 研 2024 年 04 月 24 日 | --- | --- | --- | |-----------------------------------------------------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...
天新药业:中信证券股份有限公司关于江西天新药业股份有限公司使用闲置募集资金进行现金管理的核查意见
2024-04-23 11:21
中信证券股份有限公司 关于江西天新药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 中信证券股份有限公司(以下简称"中信证券"或"保荐人")作为江西天 新药业股份有限公司(以下简称"天新药业"或"公司")首次公开发行股票并 上市的保荐人,根据《证券发行上市保荐业务管理办法(2023 年修订)》《上海证 券交易所上市公司自律监管指引第 11 号——持续督导》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求(2022 年修订)》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作(2023 年 12 月修订)》等有 关规定,对天新药业使用闲置募集资金进行现金管理的事项进行了专项核查,核 查情况如下: 一、使用闲置募集资金进行现金管理的基本情况 (一)投资目的 经中国证券监督管理委员会《关于核准江西天新药业股份有限公司首次公开 发行股票的批复》(证监许可(2022)1220 号)核准,2022 年公司在上海证券 交易所向社会公开发行 43,780,000 股,发行价为每股人民币 36.88 元,共计募集 1 资金人民币 1,614,606,400.00 元,扣除发行相关费用合计人 ...
天新药业:中信证券股份有限公司关于江西天新药业股份有限公司2023年度募集资金存放与使用情况的专项核查意见
2024-04-23 11:21
中信证券股份有限公司 关于江西天新药业股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司(以下简称"中信证券"或"保荐人")作为江西天 新药业股份有限公司(以下简称"天新药业"或"公司")首次公开发行股票并 上市的保荐人,根据《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求(2022 年修订)》《上海证券交易所股票上市规则(2023 年 8 月修 订)》及《上海证券交易所上市公司自律监管指引第 1 号——规范运作(2023 年 12 月修订)》等有关规定,对天新药业 2023 年度募集资金存放与使用情况进行 了专项核查,核查情况如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2022]1220 号"文《关于核准江 西天新药业股份有限公司首次公开发行股票的批复》核准,由主承销商中信证券 通过上海证券交易所系统采用网下向符合条件的投资者询价配售和网上向持有 上海市场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行相 结合的方式,向社会公开发行了人民币普通股(A 股)股票 43,780 ...
天新药业(603235) - 2023 Q4 - 年度财报
2024-04-23 09:01
Accounting Methods and Revenue Recognition - The company adjusts the accounting method for remaining equity after losing control of a subsidiary, either using the equity method or recognizing the difference between fair value and book value as current profit or loss[1] - Revenue from export sales is recognized based on the trade terms, with different recognition points for various trade settlement methods such as CIF, FOB, and DDP[5] - Revenue from domestic sales is recognized upon delivery to the customer's specified location and customer confirmation of receipt[9] Asset Management and Impairment - Construction in progress is recognized when economic benefits are likely to flow in and costs can be reliably measured, and is transferred to fixed assets upon reaching the intended usable state[2] - The company reviews the useful life and amortization method of finite-lived intangible assets annually, adjusting estimates and recognizing impairment if future economic benefits are no longer expected[4] - The company assesses impairment of assets related to contract costs, recognizing impairment losses if the carrying amount exceeds the expected remaining consideration minus estimated costs[10] - The company's intangible assets have a book value of 192,311,293.45 RMB at the end of the period, with a cumulative amortization of 20,669,830.54 RMB[34] - The company's engineering materials have a book value of 82,350,552.80 RMB at the end of the period, with a provision for impairment of 721,797.20 RMB[28] Government Grants and Subsidies - Government grants are recognized upon receipt, with specific criteria for recognizing grants based on expected amounts and compliance with fiscal support policies[7] - Government subsidies are recognized as deferred income and amortized over the useful life of related assets, with any remaining balance transferred to profit or loss upon disposal of the assets[11] - The company's deferred tax assets at the end of the period were RMB 85,304,542.97, with a significant portion coming from government subsidies of RMB 58,661,705.01[39][40] - Total government subsidies received increased to 138,021,872.10 RMB from 29,916,370.85 RMB, a significant growth of 361.4%[67] Financial Assets and Liabilities - The company holds no financial assets measured at fair value through profit or loss as of the reporting period, compared to RMB 230 million at the beginning of the period[13] - Bank acceptance bills amounted to RMB 50.49 million at the end of the period, all of which were not derecognized[14] - The balance of bank acceptance notes was RMB 53.29 million at the end of the period, with no bad debt provision[15] - The company's financial assets and liabilities not measured at fair value have a book value close to their fair value[169] - The fair value of receivables financing at the end of the period is RMB 3,292,184.01, classified under Level 2 fair value measurement[166] Inventory and Cost Management - Inventory increased from RMB 4.56 million to RMB 13.67 million, with significant growth in work-in-progress and finished goods[20] - Raw materials inventory decreased from RMB 83.18 million to RMB 39.66 million, while finished goods inventory increased from RMB 198.48 million to RMB 307.34 million[23] - The total inventory balance at the end of the period was RMB 492.63 million, with a provision for inventory impairment of RMB 13.67 million[23] - Operating costs decreased by 19.71% to RMB 1,161,708,799.37, primarily due to lower raw material prices and reduced manufacturing expenses[183][184] Project Investments and Progress - The budget for the Vitamin B5 project is 460,021,300 RMB, with a cumulative investment of 75.44% of the budget, and the project progress is 75.44%[25] - The Vitamin A project has a budget of 781,291,500 RMB, with a cumulative investment of 25.40% of the budget, and the project progress is 25.40%[25] - The Enterprise Research Institute project has a budget of 128,865,500 RMB, with a cumulative investment of 69.20% of the budget, and the project progress is 69.20%[25] - The fine chemical project has a budget of 500,000,000 RMB, with a cumulative investment of 2.95% of the budget, and the project progress is 2.95%[25] - The Le Ping Industrial Park cogeneration project has a budget of 350,000,000 RMB, with a cumulative investment of 12.07% of the budget, and the project progress is 12.07%[25] - The other fine chemical product project has a budget of 3,690,000,000 RMB, with a cumulative investment of 5.80% of the budget, and the project progress is 5.80%[25] - The Qingtongxia Industrial Park thermal power island project has a budget of 1,464,730,000 RMB, with a cumulative investment of 2.71% of the budget, and the project progress is 2.71%[25] - The total budget for all projects is 7,374,908,300 RMB, with a cumulative investment of 342,940,892.04 RMB[25] Financial Performance and Metrics - The company's total revenue for the year 2023 was RMB 1,881,993,019.35, with a cost of RMB 1,161,708,799.37, resulting in a gross profit of RMB 720,284,219.98[50] - B-vitamins contributed the majority of the revenue, generating RMB 1,650,309,734.61, with a cost of RMB 958,705,177.48[52] - Domestic sales accounted for RMB 782,140,234.10, while international sales contributed RMB 1,099,852,785.25[52] - The company's net profit for the current period was 475,853,298.64 RMB, a decrease from the previous period's 622,115,124.53 RMB[98] - Revenue for 2023 was 1,881,993,019.35 yuan, a decrease of 18.34% compared to the previous year[120] - Net profit attributable to shareholders was 475,853,298.64 yuan, down 23.51% year-on-year[120] - Operating cash flow increased by 20.21% to 729,212,499.59 yuan[120] - Basic earnings per share (EPS) decreased by 27.81% to 1.09 yuan per share[121] - Weighted average return on equity (ROE) dropped by 10.23 percentage points to 11.55%[121] Cash Flow and Financing Activities - The company's cash and cash equivalents increased by 238,239,548.75 RMB, reaching a total of 2,307,768,991.53 RMB at the end of the period[98] - The company's short-term borrowing increased by 100,000,000.00 RMB, with a total of 100,072,222.22 RMB at the end of the period[96] - The company's total investment in financial products was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to leasing activities was 3,383,139.22 RMB[105] - The company's total cash outflow related to financing activities was 3,171,139.22 RMB, a significant decrease from the previous period's 30,315,099.62 RMB[95] - The company's total cash outflow related to investment activities was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to operating activities was 729,212,499.59 RMB, an increase from the previous period's 606,613,170.14 RMB[98] - The company's total cash outflow related to the payment of dividends was 310,823,800.00 RMB[96] - The company's total cash outflow related to the payment of IPO issuance fees was 26,602,479.62 RMB in the previous period[95] Expenses and Costs - Total management expenses decreased to 136,349,813.27 RMB from 144,180,344.74 RMB, a reduction of 5.4%[53] - R&D expenses increased to 111,964,592.30 RMB from 89,462,842.32 RMB, a growth of 25.1%[54] - Government subsidies decreased to 47,390,378.61 RMB from 53,254,038.41 RMB, a reduction of 11.0%[55] - Investment income from bank financial products decreased to 2,454,302.84 RMB from 4,653,541.60 RMB, a reduction of 47.3%[56] - Interest income increased significantly to 74,460,498.56 RMB from 16,251,609.72 RMB, a growth of 358.2%[56] - Credit impairment losses slightly decreased to 3,159,494.22 RMB from 3,233,939.87 RMB, a reduction of 2.3%[59] - Asset impairment losses increased to -12,363,832.71 RMB from -4,157,876.36 RMB, a significant increase in losses[60] - Current income tax expense increased to 111,841,440.48 RMB from 100,786,018.29 RMB, a growth of 11.0%[63] - Total employee compensation increased to 80.16 million yuan from 74.19 million yuan, a rise of 8.05%[107] - Direct material costs rose to 7.26 million yuan from 5.29 million yuan, an increase of 37.25%[107] - Depreciation and amortization expenses surged to 12.35 million yuan from 2.98 million yuan, a significant jump of 315.08%[107] - Other expenses increased to 12.19 million yuan from 7.01 million yuan, up by 73.96%[107] - Total expenses for the period amounted to 111.96 million yuan, up from 89.46 million yuan, a 25.15% increase[107] Market and Industry Analysis - The vitamin industry faced challenges with slowing global economic growth and increased competition[128] - The company achieved domestic registration approval for folic acid raw materials and obtained EU export certification for Vitamin D3 raw materials[129] - The company completed multiple quality system expansion certifications, including ISO22000 for cholesterol and FAMI-QS certification for Vitamin A acetate and 25-hydroxy Vitamin D3[129] - R&D expenses continued to grow rapidly, driving continuous improvement in production levels[130] - The company is steadily advancing projects such as Vitamin A, Vitamin B5, and Ningxia Tianxin, ensuring sustainable development[130] - China's vitamin production in 2023 is expected to reach 434,000 tons, a 4.0% year-on-year increase, accounting for 84.4% of global production[134] - The Chinese vitamin market value in 2023 is projected to be $3.72 billion, a 16.4% year-on-year decrease[134] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[135] - The company has established a strong global competitiveness in B-group vitamins, including Vitamin B6, Vitamin B1, biotin, and folic acid[136] - The company's ABL product, used in pesticide intermediates and Vitamin B1, achieved external sales in 2022 and further expanded in 2023[136] - Vitamin business accounted for 96.30% of the company's main business revenue in 2023, being the primary factor affecting performance fluctuations[141] - Overall downstream demand for vitamins was weak in 2023, leading to increased competitive pressure on the supply side and suppressed prices, contributing to the company's performance decline[141] Corporate Governance and Compliance - The company established Tianxin International Holdings (Hong Kong) Limited in March 2023 with a registered capital of 10,000 HKD[109] - As of December 31, 2023, Tianxin International Holdings (Hong Kong) Limited reported a net loss of 92,783.10 yuan[109] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., transferred 10,000 yuan of equity in Qingtongxia Tianxin Dingheng Heating Power Co., Ltd., reducing its indirect ownership from 100% to 99.75%[113] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603235[116] - The company's auditor is Zhonghui Certified Public Accountants, and its continuous supervision sponsor is CITIC Securities[117] - The company's environmental management system is established and maintained in accordance with ISO14001 standards, emphasizing green development and circular economy[143][147] - The company has a comprehensive sales and service network centered in Shanghai, covering Asia, Europe, North America, South America, Oceania, and Africa[148] - The company has obtained various certifications, including FAMI-QS, ISO22000, BRC, Halal, Kosher, and certifications from regulatory bodies in China, the EU, the US, and Japan, ensuring access to high-end markets[149] Debt and Liabilities - The company's debt-to-asset ratio increased to 16.84% as of December 31, 2023, compared to 13.29% in the previous year[163] - Short-term borrowings: RMB 10,104.00 (within one year)[161] - Accounts payable: RMB 12,663.93 (within one year)[161] - Other payables: RMB 857.85 (within one year)[161] - Non-current liabilities due within one year: RMB 312.37[161] - Lease liabilities: RMB 530.04 (total)[162] - Total financial liabilities and contingent liabilities: RMB 25,611.19 (current period) vs RMB 12,783.00 (previous period)[162] - The company's other payables decreased from RMB 10,548,296.39 at the beginning of the period to RMB 8,578,504.58 at the end of the period[173] - The company's non-bank acceptance bills endorsed but not yet due decreased from RMB 60,012,793.35 at the beginning of the period to RMB 50,489,814.34 at the end of the period[177] - The company's government grants increased from RMB 306,156,569.99 at the beginning of the period to RMB 390,788,063.48 at the end of the period, with an increase of RMB 115,419,200.00 and a decrease of RMB 30,787,706.51 during the period[180] - The company's lease liabilities due within 1 year decreased from RMB 3,419,674.54 at the beginning of the period to RMB 3,123,735.24 at the end of the period[176] - The company's long-term payables increased from RMB 4,646,387.50 at the beginning of the period to RMB 5,095,912.47 at the end of the period[178] - The company's prepaid taxes to be transferred decreased from RMB 1,613,296.80 at the beginning of the period to RMB 1,016,999.16 at the end of the period[177] - The company's deposit and guarantee liabilities increased from RMB 175,000.00 at the beginning of the period to RMB 225,000.00 at the end of the period[175] Related Party Transactions - The company's total related party transactions amounted to RMB 3,006.56 million, with the majority coming from sales to related parties at RMB 2,105.95 million[47] - The company's subsidiaries and related parties include Zhejiang Tianxin Pharmaceutical Co., Ltd., Zhejiang Xinweishi Biotechnology Co., Ltd., and Shanghai Newrite Biotechnology Co., Ltd., among others[171] Research and Development - R&D expenses increased by 25.15% to RMB 111,964,592.30, reflecting increased investment in research and development[183] - The company's R&D expense ratio continued to increase during the reporting period, with projects such as Vitamin B5, Vitamin A, and Ningxia Tianxin progressing as planned[142] - The company's production sites have passed FDA certification, and Vitamin B6 and Vitamin B1 (hydrochloride) have obtained FDA DMF filings[143] Sales and Distribution - The company's sales model is primarily direct sales, with distributors handling wholesale or retail[140] - Main business revenue for 2023 was RMB 1,851,390,100, a decrease of 17.83%, mainly due to lower vitamin product prices[185] - Main business costs for 2023 were RMB 1,135,447,100, a decrease of 18.98%, driven by lower raw material prices and reduced manufacturing expenses[185] - Contract liabilities decreased to RMB 21,098,771.55 from RMB 23,341,621.74, indicating a reduction in prepayments from customers[196] Taxation and Deferred Taxes - Deferred tax assets and liabilities are recognized based on temporary differences between book value and tax base, with certain exceptions for transactions not affecting accounting profit or taxable income[8] - The company's internal transactions resulted in unrealized profits of RMB 126,804,672.87, with deferred tax assets of RMB 19,020,700.93[40] - The company's bad debt provision decreased by RMB 3,155,511.19, resulting in a deferred tax asset reduction of RMB 471,116.80[39] - The company's unconfirmed deferred tax assets increased by RMB 21,338,495.70, primarily due to deductible losses of RMB 17,651,718.49[45] - Deferred tax liabilities at the end of the period were RMB 4,179,272.04, primarily due to accelerated depreciation of fixed assets amounting to RMB 2,278,177.38[42] Other Financial Metrics - The total balance of deposits, guarantees, and other receivables decreased from RMB 4.27 million to RMB 2.44 million year-over-year[18] - The provision for bad debts decreased by RMB 1.5 million, resulting in a year-end balance of RMB 738,295.84[21] - The company's long-term prepaid expenses decreased by RMB 1,385,837.04, with the hazardous waste treatment center opening fee being the largest component at RMB 8,021,289.
天新药业:关于2023年第四季度经营数据的公告
2024-04-23 09:01
证券代码:603235 证券简称:天新药业 公告编号:2024-022 江西天新药业股份有限公司 关于 2023 年第四季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定,现将江西天新药业股份有限公司(以下简称"公司") 2023 年第四季度经营数据(未经审计)公告如下: 一、 2023年第四季度主要经营数据 1、主营业务分产品情况 单位:元 币种:人民币 | 产品分类 | 年 2023 | 月收入 10-12 | 2022 | 年 10-12 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | 族维生素 B | | 340,482,219.84 | | 457,578,871.42 | | -25.59% | | 其他维生素 | | 35,227,716.90 | | 60,543,528.69 | | -41.81% | | 精细化工品 | | ...